Cost Effectiveness Analysis for the Use of Extended Release Quetiapine as Adjunctive Therapy in Mexican Adult Patients with Major Depressive Disorder Non-Responders to Antidepressant Treatment

Abstract

A547treatment option as compared with escitalopram,sertraline, and venlafaxine in a matrix comparator, with regard to side effects especially sexual dysfunction, agomelatine should be considered as the most cost-effective option for treatment of depression.